Berkshire Biomedical
OperatingBerkshire Biomedical Corp
Software & AI · Dallas, TX
Berkshire Biomedical is a medical technology company focused on developing secure personalized medication management systems. Our flagship product, COPA™ supported by a $2M NIH research grant, is designed to provide reliable, biometric-controlled dispensing of liquid oral medications, addressing a critical need in chronic disease such as Opioid Use Disorder (OUD) management. Currently in the pre-revenue phase, working with the FDA, we intend to file for marketing authorization and aim to initiate clinical studies in 2025 to generate data for commercialization of COPA™ targeted for 2026.
Financials
FY2022–FY2025 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps markedA dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Team
8 people
John has served as Berkshire Biomedical’s Chief Executive Officer, President, and a member of our Board of Directors since April 2021. Mr. Timberlake has more than 30 years of life sciences experience in bringing pharmaceuticals, medical devices, and drug-device combination products to market.
John joined Berkshire Biomedical in 2018 and serves as the Head of Information Technology. Mr. Kirkpatrick has over 35 years of experience in the information technology sector, and has held leadership positions for multiple global companies. Mr. Kirkpatrick has helped develop and commercialize multiple medical software and control systems, as well as the manufacturing of devices and drugs, and research in advanced biotechnology.
Geoff has served as our Research, Development & Manufacturing Advisor since 2021. Mr. Jenkins has over thirty-five of operations and design experience specializing in start-ups and taking medical devices from concept to high volume commercial scale combining his in-depth technical background with extensive manufacturing know-how.
Dr. Olivadoti is currently an Independent Medical Affairs Consultant and is assisting Berkshire Biomedical by leading our Medical Affairs activities. Melissa has 15 years’ experience in the pharmaceutical and medical device sectors, having led and supported Medical Affairs functions in emerging and large companies.
Thomas founded Berkshire Biomedical in Dallas in 2016, and serves as the Chair of our Board of Directors. In 1988, Mr. Rouse helped found Affiliated Computer Systems, Inc. (ACS). In 1995, he founded TransFirst, a credit card financial technology firm, where he served as Chairman and CEO until 2007, when TransFirst was acquired by a private equity firm.
Tom is currently the President of Fathom Healthcare Solutions, Inc., and is responsible for leading all Market Access, Reimbursement and Health Policy aspects for Berkshire Biomedical. Tom has over 30 years of experience in leading teams in the area of Managed Markets, Health Policy, Government Affairs, and sales & marketig, and he also helped establish two buisness units, HealthNexis and AAIpharma.
Names and titles as disclosed on SEC Form C, StartEngine. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 2 of 2 annual reports (FY2024–FY2025)
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.